BlueCrest Capital Management’s Niagen Bioscience NAGE Stock Holding History

BlueCrest Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-124,510	Closed	-$523K	–	1881
2018 Q1	$523K	Buy	+124,510	New	+$652K	0.02%	748
2017 Q3	–	Sell	-23,708	Closed	-$91K	–	1122
2017 Q2	$91K	Buy	+23,708	New	+$75.1K	﹤0.01%	826

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlueCrest Capital Management's NAGE Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Niagen Bioscience (NAGE) in Q2 2018, closing a stake of 124,510 shares — an estimated $523K sold.

BlueCrest Capital Management first reported a position in NAGE in Q2 2017 and held it in 2 quarters. The position peaked at $523K in Q1 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q2 2018.

BlueCrest Capital Management reported no remaining Niagen Bioscience position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 124,510 Niagen Bioscience shares in Q2 2018, an estimated $523K.
BlueCrest Capital Management first reported a position in Niagen Bioscience in Q2 2017 and held it in 2 quarters.
BlueCrest Capital Management's Niagen Bioscience position peaked at $523K in Q1 2018.
64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.